Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Leukemia

• Publication date

  2014-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/leu.2014.13PMID 24480973
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Genetic Architecture of Multiple Myeloma

  2014cited by this paper
• Control of autophagic cell death by caspase-10 in multiple myeloma.

  2013cited by this paper
• Genome evolution during progression to breast cancer

  2013cited by this paper
• Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms

  2013cited by this paper
• Single-cell mutational profiling and clonal phylogeny in cancer

  2013cited by this paper
• GA: A Package for Genetic Algorithms in R

  2013cited by this paper
• Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells.

  2013cited by this paper
• Characterization of a Novel Mouse Model of Multiple Myeloma and Its Use in Preclinical Therapeutic Assessment

  2013cited by this paper
• Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics

  2013cited by this paper
• Minor clone provides a reservoir for relapse in multiple myeloma

  2013cited by this paper
• Targeting the BRAF V600E mutation in multiple myeloma.

  2013cited by this paper
• Clonal architecture of chronic myelomonocytic leukemias.

  2013cited by this paper
• Clonal competition with alternating dominance in multiple myeloma.

  2012cited by this paper
• Lenalidomide efficacy in activated B‐cell‐like subtype diffuse large B‐cell lymphoma is dependent upon IRF4 and cereblon expression

  2012cited by this paper
• Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

  2012cited by this paper
• Cancer stem cells as ‘units of selection’

  2012cited by this paper
• Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.

  2012cited by this paper
• Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma.

  2012cited by this paper
• The genetic architecture of multiple myeloma

  2012cited by this paper
• Molecular pathogenesis of multiple myeloma and its premalignant precursor.

  2012cited by this paper
• Clonal evolution in cancer

  2012cited by this paper
• Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

  2012cited by this paper
• The Life History of 21 Breast Cancers

  2012cited by this paper
• Intratumor heterogeneity: evolution through space and time.

  2012cited by this paper
• Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

  2012cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• IRF4 mutations in chronic lymphocytic leukemia.

  2011cited by this paper
• Initial genome sequencing and analysis of multiple myeloma

  2011cited by this paper
• Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing

  2011cited by this paper
• A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial

  2011cited by this paper
• Temporal dissection of tumorigenesis in primary cancers.

  2011cited by this paper
• Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

  2011cited by this paper
• Genetic variegation of clonal architecture and propagating cells in leukaemia

  2011cited by this paper
• A Comprehensive Survey of Clonal Diversity Measures in Barrett's Esophagus as Biomarkers of Progression to Esophageal Adenocarcinoma

  2010cited by this paper
• A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value.

  2010cited by this paper
• The patterns and dynamics of genomic instability in metastatic pancreatic cancer

  2010cited by this paper
• Clonal evolution in cancer

  2010cited by this paper
• Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype.

  2010cited by this paper
• ROCK: a breast cancer functional genomics resource

  2010cited by this paper
• Taking qPCR to a higher level: Analysis of CNV reveals the power of high throughput qPCR to enhance quantitative resolution.

  2010cited by this paper
• IRF4 addiction in multiple myeloma

  2008cited by this paper
• Interferon regulatory factor 4 and 8 in B-cell development.

  2008cited by this paper
• Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma

  2006cited by this paper
• Cancer as an evolutionary and ecological process

  2006cited by this paper
• Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma.

  2006cited by this paper
• Genomic abnormalities in monoclonal gammopathy of undetermined significance.

  2002cited by this paper
• Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes.

  1988cited by this paper
• Detection of high incidence of K-ras oncogenes during human colon tumorigenesis

  1987cited by this paper
• The clonal evolution of tumor cell populations.

  1976cited by this paper

• Interpreting cancer genetics through a two-step "evolutionary cascade hypothesis": bridging neutral and selective perspectives.

  2026cites this paper
• Application of single nucleotide polymorphism array (SNP array) derived median copy number state for monitoring the clonal burden of the chromosomal aberrations in myelodysplastic neoplasms.

  2026cites this paper
• Integrative analysis of bulk and single-cell gene expression profiles to identify bone marrow mesenchymal cell heterogeneity and prognostic significance in multiple myeloma

  2025cites this paper
• 基因突变在多发性骨髓瘤预后及治疗中的价值

  2025cites this paper
• Clinical implications of ctDNA-based minimal residual disease detection in newly diagnosed peripheral T-cell lymphoma: a single-center cohort study

  2025cites this paper
• Multiple Myeloma Insights from Single-Cell Analysis: Clonal Evolution, the Microenvironment, Therapy Evasion, and Clinical Implications

  2025cites this paper
• Single mutation tunes IRF4 function and mediates B cell character to ameliorate murine lupus

  2025cites this paper
• Single-cell sequencing reveals the mechanisms of multiple myeloma progression: clarity or confusion?

  2025cites this paper
• A live cell biosensor protocol for high-resolution screening of therapy-resistant cancer cells

  2025cites this paper
• Multiple Myeloma and Precursor Plasma Cell Disorders: From Emerging Driver Mutations to Current and Future Therapeutic Strategies

  2025cites this paper
• Single-Cell RNA Sequencing before and after Light Chain Escape Reveals Intrapatient Multiple Myeloma Subpopulations with Divergent Osteolytic Gene Expression

  2024cites this paper
• Novel Insights into the Initiation, Evolution, and Progression of Multiple Myeloma by Multi-Omics Investigation

  2024influential citation
• A systematic literature review on clonal evolution events preceding relapse in multiple myeloma.

  2024cites this paper
• Cell competition and cancer from Drosophila to mammals

  2024cites this paper
• Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer.

  2024cites this paper
• The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

  2024cites this paper
• Approach to High-Risk Multiple Myeloma.

  2024cites this paper
• Phenotype-structured model of intra-clonal heterogeneity and drug resistance in multiple myeloma.

  2023cites this paper
• Antibody–Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?

  2023cites this paper
• Essential procedures of single-cell RNA sequencing in multiple myeloma and its translational value

  2023cites this paper
• Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma

  2023cites this paper
• Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease.

  2023cites this paper
• Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis

  2023cites this paper
• Dynamic single-cell RNA-seq analysis reveals distinct tumor program associated with microenvironmental remodeling and drug sensitivity in multiple myeloma

  2023cites this paper
• Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma

  2023cites this paper
• Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level

  2023cites this paper
• Immunogenic cell death triggered by impaired deubiquitination in multiple myeloma relies on dysregulated type I interferon signaling

  2023cites this paper
• Cancer progression: a single cell perspective.

  2023cites this paper
• Single-cell technologies in multiple myeloma: new insights into disease pathogenesis and translational implications

  2023cites this paper
• Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma

  2023cites this paper
• Immune Checkpoint Inhibitor Related Rheumatological Complications: Cooperation between Rheumatologists and Oncologists

  2023cites this paper
• The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring “Multiple Myelomas”

  2022cites this paper
• Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing

  2022cites this paper
• The Role of Clonal Evolution on Progression, Blood Parameters, and Response to Therapy in Multiple Myeloma

  2022cites this paper
• The Molecular Subtype of Adult Acute Lymphoblastic Leukemia Samples Determines the Engraftment Site and Proliferation Kinetics in Patient-Derived Xenograft Models

  2022cites this paper
• The yin–yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma

  2022cites this paper
• Multiple Myeloma

  2022cites this paper
• OnkoCampus

  2022cites this paper
• Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application

  2022cites this paper
• Clinical characteristics and prognostic significance of immunoglobulin isotype switch in patients with multiple myelom

  2022cites this paper
• Cancer evolution: special focus on the immune aspect of cancer.

  2022cites this paper
• Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma

  2022cites this paper
• Single‐cell RNA‐seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma

  2022cites this paper
• Multiple Myeloma Therapy: Emerging Trends and Challenges

  2022cites this paper
• Single-cell profiling of tumour evolution in multiple myeloma — opportunities for precision medicine

  2022cites this paper
• Correlation of plasma cell assessment by phenotypic methods and molecular profiles by NGS in patients with plasma cell dyscrasias

  2022cites this paper
• Single-Cell Sequencing Technologies in Precision Oncology.

  2022cites this paper
• Structural determinants of the IRF4/DNA homodimeric complex

  2021cites this paper
• Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial

  2021cites this paper
• Undetectable MRD can change the deal.

  2021cites this paper
• Early and late relapses of multiple myeloma after autologous haematopoietic stem cell transplantation

  2021cites this paper
• Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study

  2021cites this paper
• Genome Instability in Multiple Myeloma: Facts and Factors

  2021cites this paper
• Deciphering intratumoral heterogeneity using integrated clonal tracking and single-cell transcriptome analyses

  2021cites this paper
• Bringing precision oncology to cellular resolution with single-cell genomics

  2021cites this paper
• The Immunity‐malignancy equilibrium in multiple myeloma: lessons from oncogenic events in plasma cells

  2021cites this paper
• Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression

  2021cites this paper
• Clonal Evolution of Multiple Myeloma—Clinical and Diagnostic Implications

  2021cites this paper
• Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma

  2021cites this paper
• Analysis of Intratumoral Heterogeneity in Myelodysplastic Syndromes with Isolated del(5q) Using a Single Cell Approach

  2021cites this paper
• Genetic and Non-Genetic Mechanisms Underlying Cancer Evolution

  2021cites this paper
• A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma

  2021cites this paper
• Chromothripsis as a pathogenic driver of multiple myeloma.

  2021cites this paper
• Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma

  2021cites this paper
• Branching clonal evolution patterns predominate mutational landscape in multiple myeloma

  2021cites this paper
• Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH

  2021cites this paper
• The molecular pathogenesis of multiple myeloma

  2020cites this paper
• To portray clonal evolution in blood cancer, count your stem cells.

  2020cites this paper
• 1st SOHO Italy, Clinical and Biological School of Multiple Myeloma

  2020cites this paper
• Cancer evolution: A means by which tumors evade treatment.

  2020cites this paper
• A Single Surviving Cancer Cell Reflects the Mutational Landscape of Relapsed Multiple Myeloma

  2020cites this paper
• Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma

  2020cites this paper
• Post-transcriptional control of cellular differentiation by the RNA exosome complex

  2020cites this paper
• Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials

  2020cites this paper
• Evolution and structure of clinically relevant gene fusions in multiple myeloma

  2020cites this paper
• Biological and Translational Considerations regarding the Recent Therapeutic Successes and Upcoming Challenges for Multiple Myeloma.

  2020cites this paper
• Liquid biopsies for multiple myeloma in a time of precision medicine

  2020cites this paper
• Second malignancies in multiple myeloma; emerging patterns and future directions.

  2020cites this paper
• Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)

  2020cites this paper
• Molecular basis of clonal evolution in multiple myeloma

  2020cites this paper
• GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice

  2020cites this paper
• Deep sequencing as an approach to understanding the complexity and improving the treatment of multiple myeloma

  2020cites this paper
• Molecular Links Between Angiogenesis and Neuroendocrine Phenotypes in Prostate Cancer Progression

  2020cites this paper
• Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines

  2020cites this paper
• The impact of cytogenetic evolution and acquisition of del(17p) on the prognosis of patients with multiple myeloma

  2020cites this paper
• The RNA Exosome and Human Disease.

  2020cites this paper
• Multiple Myeloma: Methods and Protocols

  2020influential citation
• Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma.

  2020influential citation
• Mathematical Methods for Modelling Biological Heterogeneity

  2019cites this paper
• Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis

  2019cites this paper
• Inferring clonal heterogeneity in cancer using SNP arrays and whole genome sequencing

  2019cites this paper
• 1 High-Risk Multiple Myeloma : Integrated Clinical 2 and Omics Approach Dissects the Neoplastic Clone 3 and the Tumor Microenvironment 4

  2019cites this paper
• The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies

  2019cites this paper
• Molecular signatures of multiple myeloma progression through single cell RNA-Seq

  2019cites this paper
• The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma

  2019cites this paper
• Hybrid models in biomedical applications

  2019cites this paper
• UDC : 519 . 8 Hybrid models in biomedical applications

  2019cites this paper
• Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis

  2019cites this paper
• High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment

  2019cites this paper
• Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients

  2019cites this paper